Washington reached a $518 million settlement with drug distributors McKesson Corp., AmerisourceBergen Corp. and Cardinal Health, ending a months-long trial over the companies’ alleged role in fueling the opioid epidemic in the state, the three companies announced on May 3.
Anat Ashkenazi was tapped to take over as chief financial officer of Eli Lilly following the abrupt resignation of Josh Smiley, who departed the company following allegations of an inappropriate relationship with an employee.
Johnson & Johnson was ordered by a New Jersey state jury to pay punitive damages of $750 million to four plaintiffs who allege that the company’s Baby Powder caused their cancer, a ruling that will be reduced to around $185 million because of state laws, according to a lawyer for the plaintiffs and J&J.
A federal judge tossed out whistleblower lawsuits alleging that pharmaceutical giants Eli Lilly and Bayer used nurses to illegally boost sales of various prescription drugs in a kickback scheme.
Novartis AG laid the blame for the manipulation of data behind the company’s $2.1 million gene therapy Zolgensma at the feet of the former executives Brian and Allan Kaspar.
Reckitt Benckiser Group agreed to pay $1.4 billion to settle a U.S. investigation into the sales and marketing of Suboxone Film, a product managed by the spinout company Indivior.
Bayer shares fell by as much as 5 percent after a California couple were awarded more than $2 billion in the largest U.S. jury penalty over allegations the company’s Roundup weed killer causes cancer.
U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc. of orchestrating a sweeping scheme with 19 other drug companies to inflate drug prices – sometimes by more than 1,000 percent – and stifle competition for generic drugs, state prosecutors said.
A Missouri Supreme Court ruling on talc lawsuits could reduce the liability and number of large trials Johnson & Johnson faces over allegations the company’s talc products, including baby powder, cause cancer.
Swiss pharma giant Novartis has found itself at the center of a legal battle that could determine if the company engaged in a research project that was a kickback in disguise.